Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinomaAustin G. Duffy, Tim F. Greten, David Venzon et al.|Journal of Hepatology|2016Cited by 817
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Fable Zustovich, Giuseppe Cabibbo et al.|Journal of Hepatology|2023Cited by 62
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Johann von Felden, Giuseppe Cabibbo et al.|Hepatology|2024Cited by 52
First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.Kyriakos P. Papadopoulos, Glenn S. Kroog, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2019Cited by 38
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Calogero Cammà, Bernhard Scheiner et al.|JAMA Oncology|2024Cited by 37